0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PD-L1

PD-L1

Brief Information

Name:Programmed death-ligand 1
Target Synonym:Programmed Cell Death 1 Ligand 1,PDCD1L1,B7H1,PDL1,Programmed Death Ligand 1,B7-H1,B7-H,B7-H1 Antigen,CD274,B7 homolog 1,PDCD1 ligand 1,PD-L1,PDCD1LG1,CD274 Molecule,CD274 Antigen,HPD-L1
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:59
Lastest Research Phase:NDA/BLA

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
PD1-H82A3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
PD1-H82A3-structure
PD1-H82A3-sds
PD1-H82A3-elisa_1
PD1-H52H3 Human Human PD-L1 / B7-H1 (19-134) Protein, His Tag (MALS verified)
PD1-H52H3-structure
PD1-H52H3-sds
PD1-H52H3-elisa_1
PD1-C52H3 Canine Canine PD-L1 / B7-H1 Protein, Fc Tag
PD1-C52H3-structure
PD1-C52H3-sds
PDL-H82E4 Human Biotinylated Human PD-L1 / B7-H1 (19-134) Protein, His,Avitag™ (recommended for biopanning) (MALS verified)
PDL-H82E4-structure
PDL-H82E4-sds
PDL-H82E4-elisa_1
PDL-R52H6 Rabbit Rabbit PD-L1 / B7-H1 Protein, His Tag
PDL-R52H6-structure
PDL-R52H6-sds
PDL-H5250 Human Human PD-L1 / B7-H1 Protein, Llama IgG2b Fc Tag, low endotoxin
PDL-H5250-structure
PDL-H5250-sds
PDL-H5250-elisa_1
PDL-H82F2 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)
PDL-H82F2-structure
PDL-H82F2-sds
PDL-H82F2-elisa_1
PD1-M52A2 Mouse Mouse PD-L1 / B7-H1 Protein, Mouse IgG2a Fc Tag, low endotoxin
PD1-M52A2-structure
PD1-M52A2-sds
PD1-M52A2-elisa_1
PD1-H82E5 Human Biotinylated Human PD-L1 / B7-H1 Protein, Avitag™,His Tag (recommended for biopanning, MALS verified)
PD1-H82E5-structure
PD1-H82E5-sds
PD1-H82E5-elisa_1
PD1-M82F5 Mouse Biotinylated Mouse PD-L1 / B7-H1 Protein, Fc,Avitag™
PD1-M82F5-structure
PD1-M82F5-sds
PD1-M82F5-elisa_1
PD1-M5220 Mouse Mouse PD-L1 / B7-H1 Protein, His Tag
PD1-M5220-structure
PD1-M5220-sds
PD1-M5220-elisa_2
PD1-M5251 Mouse Mouse PD-L1 / B7-H1 Protein, Fc Tag
PD1-M5251-structure
PD1-M5251-sds
PD1-M5251-elisa_1
PD1-H52A3 Human Human PD-L1 / B7-H1 Protein, Mouse IgG1 Fc Tag, low endotoxin (MALS verified)
PD1-H52A3-structure
PD1-H52A3-sds
PD1-H52A3-hplc
PD1-H52A3-elisa_1
PD1-C52H4 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His Tag
PD1-C52H4-structure
PD1-C52H4-sds
PD1-C52H4-elisa_1
PD1-C52H4-elisa_2
PD1-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc Tag
PD1-C5253-structure
PD1-C5253-sds
PD1-C5253-elisa_1
PD1-H82F3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™,His Tag (MALS verified)
PD1-H82F3-structure
PD1-H82F3-sds
PD1-H82F3-elisa_1
PD1-H5282 Human Human PD-L1 / B7-H1 Protein, Strep Tag
PD1-H5282-structure
PD1-H5282-sds
PD1-H5282-elisa_1
PD1-H5258 Human Human PD-L1 / B7-H1 Protein, Fc Tag (MALS verified)
PD1-H5258-structure
PD1-H5258-sds
PD1-H5258-hplc
PD1-H5258-elisa_1
PD1-H5229 Human Human PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PD1-H5229-structure
PD1-H5229-sds
PD1-H5229-hplc
PD1-H5229-elisa_1
PD1-H5229-elisa_2

Part of Bioactivity data

PD1-H82F3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Biotinylated Human PD-L1, Fc,Avitag,His Tag (Cat.No. PD1-H82F3) can bind to 293 cell overexpressing human PD-1. The concentration of PD-L1 used is 1 μg/mL (Routinely tested).

PD1-H82F3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of Biotinylated Human PD-L1, Fc,Avitag,His Tag (Cat. No. PD1-H82F3) to 293 overexpressing PD-1 was inhibited by increasing concentration of neutralizing anti-PD-1 antibody. The concentration of PD-L1 used is 2 μg/mL. The IC50 is 0.64 μg/mL (Routinely tested).

PD1-M5220-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).

PD1-M5220-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Mouse PD-L1, His Tag (Cat. No. PD1-M5220) on CM5 Chip via Anti-His antibody can bind Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) with an affinity constant of 1.37 μM as determined in SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

PD-L1,CD274,B7-H1,PDCD1L1,PDCD1LG1

Background

Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Avelumab PF-06834635; MSB-0010718C Approved Merck Serono Bavencio EU Carcinoma, Transitional Cell Merck Europe Bv 2017-03-23 Chordoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Esophageal Squamous Cell Carcinoma; Peritoneal Neoplasms; Colorectal Neoplasms; Vulvar Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Lymphoma, Large B-Cell, Diffuse; Papillomavirus Infections; Carcinoma, Ovarian Epithelial; Glioblastoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Anus Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Solid tumours Details
Durvalumab 28X28X9-OKV (UNII code); MEDI-4736 Approved Medimmune Llc 英飞凡, Imfimzi United States Small Cell Lung Carcinoma Astrazeneca Uk Ltd 2018-02-16 Lymphoma, Non-Hodgkin; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Fallopian Tube Neoplasms; Lymphoma, T-Cell, Cutaneous; Lymphoma; Digestive System Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Uterine Cervical Neoplasms; Esophageal Neoplasms; Biliary Tract Neoplasms; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Carcinoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Solid tumours; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Papillomavirus Infections; Urinary Bladder Neoplasms; Multiple Myeloma Details
Atezolizumab RO-5541267; 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A Approved Genentech Inc 泰圣奇, Tecentriq Mainland China Carcinoma, Non-Small-Cell Lung Roche (China) Holding Ltd 2016-05-18 Thymoma; Cholangiocarcinoma; Peritoneal Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Bile Duct Neoplasms; Genital Neoplasms, Female; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Metastatic breast cancer; Neoplasms, Unknown Primary; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Prostatic Neoplasms; Uterine Neoplasms; Gallbladder Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Urogenital Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Neoplasm Metastasis; Liposarcoma, Myxoid; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Transitional Cell; Solid tumours; Head and Neck Neoplasms; Kidney Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Papillom Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) Phase 1 Clinical Tianjin Mycure Medical Technology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
LY-3415244 LY-3415244 Phase 1 Clinical Eli Lilly And Company Neoplasms Details
BMS-986189 BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 Phase 1 Clinical Bristol-Myers Squibb Company Sepsis Details
KD-045 (Nanjing KAEDI Biotech) KD-045 Phase 1 Clinical Nanjing Kaedi Biotechnology Co Ltd Neoplasms Details
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) Phase 2 Clinical Changhai Hospital Of Shanghai Pancreatic Neoplasms Details
艾姆地芬 Phase 1 Clinical Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences Solid tumours Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase 1 Clinical Hunan Zhaotai Yongren Biotech Carcinoma, Non-Small-Cell Lung Details
INBRX-105 INBRX-105 Phase 1 Clinical Inhibrx Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Esophageal adenocarcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma Details
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) Phase 1 Clinical The Second Hospital Of Nanjing Medical University Carcinoma, Hepatocellular Details
HLX-20 HLX-20 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Neoplasms Details
FPT-155 CD80-Fc; FPT-155 Phase 1 Clinical Five Prime Therapeutics Neoplasms Details
BMS-936559 MDX-1105; BMS-936559 Phase 3 Clinical Bristol-Myers Squibb Company Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Shock, Septic; Hodgkin Disease; Sepsis; Multiple Myeloma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma Details
RG-6084 RG-6084 Phase 1 Clinical F. Hoffmann-La Roche Ltd Hepatitis B Details
MCLA-145 MCLA-145 Phase 1 Clinical Incyte Corp, Merus Neoplasms Details
IBI-323 IBI323; IBI-323 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
Pd-1-pik Pd-1-pik Phase 1 Clinical Department Of Integrative Medicine, Huashan Hospital Of Fudan University, Shanghai, China Glioblastoma Details
LOR-S03 CDX-527; LOR-A04; LOR-S01; LOR-S03 Phase 1 Clinical Celldex Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) Phase 1 Clinical Sichuan University Peritoneal Neoplasms Details
CA-170 CA-170; AUPM-170 Phase 2 Clinical Aurigene Solid tumours; Neoplasms Details
CK-301 CK-301 Phase 1 Clinical Dana-Farber Cancer Institute Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Mesothelioma; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Melanoma Details
ADG-104 ADG-104; ADG104 Phase 2 Clinical Neoplasms Details
Carrizumab Details
89Zr-durvalumab Phase 2 Clinical Radboud University Nijmegen Head and Neck Neoplasms Details
Lodapolimab LY-3300054 Phase 1 Clinical Eli Lilly And Company Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
18F-BMS-986192 BMS-986192-[18F] Clinical Bristol-Myers Squibb Company Neoplasms Details
Recombinant human anti-PD-L1 monoclonal antibody (Guilin Sanjin) Phase 2 Clinical Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Penile Neoplasms Details
Recombinant anti-PD-L1 human monoclonal antibody (Hisun Pharm) HS-636 Phase 2 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Primary mediastinal B cell lymphoma Details
SHR-1316 SHR-1316 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details
PM-8001 6MW3111; PM-8001 Phase 2 Clinical Pumis Biotechnology (Zhuhai) Co Ltd Solid tumours; Lung Neoplasms Details
IBI318 IBI-318; LY-3434172; LY3434172 Phase 2 Clinical Eli Lilly And Company, Innovent Biologics(Suzhou) Co Ltd Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
Human source and Fc engineered monoclonal antibody (MabSpace) MSB-2311 Phase 1 Clinical Mabspace Biosciences Solid tumours Details
FAZ-053 LAE-005; FAZ-053 Phase 2 Clinical Novartis Pharma Ag Solid tumours; Triple Negative Breast Neoplasms; Chordoma; Sarcoma, Alveolar Soft Part Details
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) Phase 1 Clinical Jiangsu Huaiyu Pharmaceutical Co Ltd Solid tumours Details
GS-4224 GS-4224 Phase 1 Clinical Gilead Sciences Inc Solid tumours; Hepatitis B Details
BGB-A333 BGB-A333 Phase 1 Clinical Beigene Ltd Solid tumours; Neoplasms Details
KL-A167 A-167; KL-A167; HBM-9167 Phase 2 Clinical Sichuan Kelun Botai Biomedicine Co Ltd Lymphoma, B-Cell; Solid tumours; Hodgkin Disease; Nasopharyngeal Carcinoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma Details
GR-1405 GR-1405 Phase 3 Clinical Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd Head and Neck Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Nasopharyngeal Carcinoma; Lymphoma Details
MAX-10181 MAX-10181; MAX-1 Phase 1 Clinical Guangzhou Maxinovel Pharmaceiticals Co Ltd Solid tumours Details
ND-021 ND-021; NM21-1480; CS-2006; CS2006 Phase 2 Clinical Numab Therapeutics Ag Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Durvalumab/Gefitinib Phase 2 Clinical Medimmune Carcinoma, Non-Small-Cell Lung Details
Durvalumab/Selumetinib sulfate Phase 1 Clinical Astrazeneca Plc Neoplasms Details
MT-6402 Phase 1 Clinical Molecular Templates Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung Details
IMC-001 IMC-001; STI-3031; STI-A1015 Phase 2 Clinical Sorrento Therapeutics Solid tumours; Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Neoplasm Metastasis; Gastrointestinal Neoplasms Details
TST-005 TST-005; TST005 Phase 1 Clinical Neoplasms Details
Anti PD-L1 monoclonal antibody (Biocad) BCD-135 Phase 1 Clinical Biocad Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
ALPN-202 ALPN-202 Phase 1 Clinical Alpine Immune Sciences Solid tumours; Lymphoma Details
IMM-2510 IMM-2510 Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours Details
Q-1802 Q-1802 Phase 1 Clinical Qiyu Biotechnology (Shanghai) Co Ltd Solid tumours Details
JS-003 JS-003 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms Details
ABSK-043 ABSK043 Phase 1 Clinical Abbisko Therapeutics Solid tumours; Neoplasms Details
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) LP-002 Phase 2 Clinical Taizhou Houde Aoke Technology Co Ltd Solid tumours; Lymphoma, B-Cell; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma Details
IMM2505 IMM2505 Phase 1 Clinical Shenghe (China) Biopharmaceutical Co Ltd Solid tumours Details
QLF31907 QLF31907; QLF-31907 Qilu Pharmaceutical Co Ltd Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Glioma; Neoplasm Metastasis Details
GNC-038 GNC-038 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
RC-98 RC-98; RC98 Phase 1 Clinical Rc Biotechnologies Ltd Solid tumours Details
TQB-2450 APL-502; CBT-502; TQ-B2450 Phase 3 Clinical Cbt Stroke; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma; Uterine Cervical Neoplasms; Lung Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Endometrial Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Liver Neoplasms; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Genital Diseases, Female; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Head and Neck Neoplasms; Biliary Tract Neoplasms; Lymphoma, B-Cell; Solid tumours Details
Recombinant anti-PD-L1/TGF-β bispecific antibody Y101D; Y-101D Phase 1 Clinical Wuhan Yzy Biopharma Solid tumours Details
ABL-503 ABL-503; TJ-L14B/ABL503; ABL503 Phase 1 Clinical Abl Bio Inc Solid tumours Details
BR-102 BR102 Phase 1 Clinical Zhejiang Borui Biopharmaceutical Co Ltd Solid tumours Details
Cosibelimab CK-301; TG-1501 Phase 3 Clinical Tg Therapeutics Lymphoma; Carcinoma, Non-Small-Cell Lung Details
PF-07257876 Phase 1 Clinical Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung Details
ES101 ES101 Phase 2 Clinical Inhibrx Solid tumours; Thoracic Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung Details
CX-072 CX-072 Phase 2 Clinical Cytomx Therapeutics Solid tumours; Triple Negative Breast Neoplasms; Breast Neoplasms; Lymphoma; Melanoma Details
89Zr-KN035(Wuxi No. 4 People's Hospital) Clinical Wuxi No. 4 People Solid tumours Details
GI-101 GI-101 Phase 2 Clinical Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
FS-222 FS-222 Phase 1 Clinical F-star Beta Ltd Neoplasm Metastasis Details
GNC-035 quadr-specific antibody(baili) GNC-035 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours Details
FH-2001 FH-2001 Solid tumours Details
IGV-001 IGV-001 Phase 2 Clinical Thomas Jefferson University Glioblastoma Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
FS 118 FS-118 Phase 2 Clinical Merck Serono, F-Star Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasm Metastasis Details
GEN-1046 GEN1046; PD-L1x4-1BB; DuoBody-PD-L1x4-1BB Phase 2 Clinical Biontech Se, Genmab Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
ATG-101 ATG-101 Phase 1 Clinical Antengene Corporation Co Ltd Hematologic Neoplasms; Solid tumours; Lymphoma, Non-Hodgkin Details
Recombinant human anti-PD-L1 monoclonal antibody (Zhaoke Oncology) ZKAB001; STI-A1014; STIA-1014 Phase 3 Clinical Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd Biliary Tract Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Osteosarcoma; Bile Duct Neoplasms; Melanoma; Uterine Cervical Neoplasms Details
HB-0025 HB0025 Phase 1 Clinical Huabo Biological Medicine Technology (Shanghai) Co Ltd, Shanghai Huaao Tai Biopharma Co Ltd Solid tumours Details
SHR-1701 SHR-1701 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
KN-046 KN046; KN-046 Phase 3 Clinical Suzhou Alphamab Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Thymus Neoplasms; Carcinoma, Squamous Cell; Lymphoma; Esophageal Squamous Cell Carcinoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details

This web search service is supported by Google Inc.

totop